Tag: Biogen
Biogen announces FDA approval of Plegridy intramuscular administration for multiple sclerosis
Biogen has announced that the US Food and Drug Administration (FDA) has approved a new intramuscular (IM) injection route of administration for Plegridy (peginterferon...
Biogen advances research to improve outcomes for patients with multiple sclerosis
Through its research initiatives, Biogen aims to identify new ways to manage and monitor multiple sclerosis (MS) disease progression and provide physicians with...
Biogen buys Pfizer’s unwanted neuro med for US$75M
Biogen has bought a phase 2-ready schizophrenia drug. They will pay a US$75 million upfront for the therapy, with a follow-up payment of US$515...
AFFINITY Phase 2 MS trial begins
Biogen has announced the recent initiation of the Phase 2 clinical trial AFFINITY, designed to evaluate opicinumab—a human monoclonal antibody targeting LINGO-1—as an investigational...
NICE recommends Zinbryta (daclizumab) for relapsing-remitting multiple sclerosis
The National Institute for Health and Care Excellence (NICE) has recommended ZINBRYTA (daclizumab) from Biogen for the treatment of adult patients living with relapsing-remitting...
Siemens Healthineers and Biogen to jointly develop new MRI tools for...
Siemens Healthineers and Biogen have announced that the companies plan to jointly develop magnetic resonance imaging (MRI) applications with the intent of quantifying key...
